27 related articles for article (PubMed ID: 38693052)
1. Impact of a Best Practices Program in Patients with Relapsed/Refractory Multiple Myeloma Receiving Selinexor.
Gordan LN; Ray D; Ijioma SC; Dranitsaris G; Warner A; Heritage T; Fink M; Wenk D; Chadwick P; Khrystolubova N; Peles S
Curr Oncol; 2024 Jan; 31(1):501-510. PubMed ID: 38248119
[TBL] [Abstract][Full Text] [Related]
2. Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups.
Orlowski RZ; Moreau P; Niesvizky R; Ludwig H; Oriol A; Chng WJ; Goldschmidt H; Yang Z; Kimball AS; Dimopoulos M
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):522-530.e1. PubMed ID: 31160237
[TBL] [Abstract][Full Text] [Related]
3. Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma.
Bahlis NJ; Sutherland H; White D; Sebag M; Lentzsch S; Kotb R; Venner CP; Gasparetto C; Del Col A; Neri P; Reece D; Kauffman M; Shacham S; Unger TJ; Jeha J; Saint-Martin JR; Shah J; Chen C
Blood; 2018 Dec; 132(24):2546-2554. PubMed ID: 30352784
[TBL] [Abstract][Full Text] [Related]
4. Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
Mateos MV; Gavriatopoulou M; Facon T; Auner HW; Leleu X; Hájek R; Dimopoulos MA; Delimpasi S; Simonova M; Špička I; Pour L; Kriachok I; Pylypenko H; Doronin V; Usenko G; Benjamin R; Dolai TK; Sinha DK; Venner CP; Garg M; Stevens DA; Quach H; Jagannath S; Moreau P; Levy M; Badros AZ; Anderson LD; Bahlis NJ; Cavo M; Chai Y; Jeha J; Arazy M; Shah J; Shacham S; Kauffman MG; Richardson PG; Grosicki S
J Hematol Oncol; 2021 Apr; 14(1):59. PubMed ID: 33849608
[TBL] [Abstract][Full Text] [Related]
5. Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: Extended follow-up subgroup analysis of the BOSTON trial.
Mateos MV; Engelhardt M; Leleu X; Mesa MG; Cavo M; Dimopoulos M; Bianco M; Merlo GM; Porte C; Richardson PG; Moreau P
Eur J Haematol; 2024 May; ():. PubMed ID: 38693052
[TBL] [Abstract][Full Text] [Related]
6. Selinexor for the treatment of patients with relapsed or refractory multiple myeloma.
Babar A; Babar M; Zubair H; Shahid A; Rafique S; Bano M; Waleed MS; Khan M; Inayat A; Safi D
J Oncol Pharm Pract; 2024 Apr; 30(3):535-546. PubMed ID: 38454813
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of selinexor-based regimens for relapsed/refractory multiple myeloma: a systematic review of literature.
Masood A; Iqbal Q; Ehsan H; Davis JA; Hansen DK; Hashmi H
Ann Hematol; 2022 Dec; 101(12):2601-2610. PubMed ID: 36214853
[TBL] [Abstract][Full Text] [Related]
8. Selinexor-Bortezomib-Dexamethasone: A Review in Previously Treated Multiple Myeloma.
Syed YY
Target Oncol; 2023 Mar; 18(2):303-310. PubMed ID: 36622630
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trials.
Zheng Y; Shen H; Xu L; Feng J; Tang H; Zhang N; Chen X; Gao G
J Immunol Res; 2018; 2018():7646913. PubMed ID: 30050957
[TBL] [Abstract][Full Text] [Related]
10. Clinical Utility of Selinexor/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: A Review of Current Evidence and Patient Selection.
Malandrakis P; Ntanasis-Stathopoulos I; Gavriatopoulou M; Terpos E
Onco Targets Ther; 2020; 13():6405-6416. PubMed ID: 32669858
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]